Condition: Non-muscle Invasive Bladder Cancer (NMIBC) · Sponsor: Lahey Clinic
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
This description comes directly from the study's public registry record.
Linda Topjian · 7817448420 · Linda.M.Topjian@lahey.org
Colette Osborne · Colette.A.Osborne@lahey.org
Always discuss trial participation with your own doctor first.
| Lahey Hospital and Medical Center | Burlington, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07187063